Replies to post #19957 on RespireRx Pharmaceuticals Inc (RSPI)

[Aiming4]

Gfp - RD1 should provide info on maintenance of analgesia, regardless of whether it provides any additional insight on RD treatment at 1500 mg - is that correct?

So while Cortex wouldn't have analgesia proof at 2100mg, good analgesia results at 1500mg would still probably be sufficient for a reasonable partnership deal.




#Board-3252

[neuroinv]

Since the RD1 results are not going to be 'mush', I see no reason to speculate about that.

NeuroInvestment